GSP Crop Science Ltd
Company mejorly focusing on fungiside and insecticide and related pesticide
- Market Cap ₹ 2,158 Cr.
- Current Price ₹ 464
- High / Low ₹ 470 / 327
- Stock P/E 23.2
- Book Value ₹ 158
- Dividend Yield 0.00 %
- ROCE 19.2 %
- ROE 16.1 %
- Face Value ₹ 10.0
Pros
Cons
- The company has delivered a poor sales growth of 7.15% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 929 | 1,137 | 1,521 | 1,309 | 1,226 | 1,409 | 1,606 | |
| 876 | 1,043 | 1,389 | 1,249 | 1,125 | 1,275 | 1,456 | |
| Operating Profit | 53 | 94 | 133 | 60 | 101 | 133 | 150 |
| OPM % | 6% | 8% | 9% | 5% | 8% | 9% | 9% |
| 13 | 34 | 11 | 6 | 13 | 18 | 17 | |
| Interest | 23 | 18 | 23 | 37 | 34 | 30 | 32 |
| Depreciation | 17 | 18 | 18 | 20 | 19 | 19 | 16 |
| Profit before tax | 26 | 93 | 102 | 10 | 61 | 102 | 119 |
| Tax % | 27% | 25% | 25% | 14% | 25% | 25% | 24% |
| 19 | 70 | 76 | 8 | 46 | 76 | 90 | |
| EPS in Rs | 64.99 | 235.99 | 257.87 | 29.95 | 176.91 | 19.56 | 19.31 |
| Dividend Payout % | 8% | 4% | 4% | 7% | 6% | 4% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 7% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 126% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 16% |
| Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 29 | 29 | 29 | 27 | 26 | 39 | 47 |
| Reserves | 305 | 372 | 446 | 329 | 323 | 383 | 688 |
| 152 | 139 | 320 | 324 | 235 | 246 | 216 | |
| 272 | 362 | 453 | 429 | 362 | 483 | 530 | |
| Total Liabilities | 759 | 903 | 1,248 | 1,110 | 947 | 1,151 | 1,481 |
| 152 | 153 | 157 | 156 | 165 | 152 | 165 | |
| CWIP | 7 | 8 | 9 | 15 | 6 | 20 | 23 |
| Investments | 37 | 0 | 2 | 3 | 8 | 23 | 37 |
| 563 | 742 | 1,081 | 936 | 768 | 956 | 1,256 | |
| Total Assets | 759 | 903 | 1,248 | 1,110 | 947 | 1,151 | 1,481 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 71 | -67 | 101 | 172 | 50 | |||
| 21 | -17 | -45 | 17 | -48 | |||
| -50 | 158 | -159 | -177 | -22 | |||
| Net Cash Flow | 42 | 73 | -103 | 12 | -20 | ||
| Free Cash Flow | 53 | -113 | 69 | 179 | 18 | ||
| CFO/OP | 97% | -45% | 212% | 183% | 54% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 111 | 98 | 107 | 124 | 97 | 100 | 127 |
| Inventory Days | 112 | 128 | 124 | 123 | 97 | 147 | 114 |
| Days Payable | 113 | 135 | 108 | 124 | 102 | 143 | 138 |
| Cash Conversion Cycle | 110 | 90 | 123 | 124 | 91 | 104 | 102 |
| Working Capital Days | 45 | 56 | 64 | 55 | 48 | 42 | 57 |
| ROCE % | 22% | 19% | 6% | 15% | 21% | 19% |
Documents
Announcements
-
Disclosure Under Regulation 30 (5) Of The SEBI (LODR) Regulations 2015
14h - Board approved FY26 audited results, Rs1 dividend, and appointed Pranav Chitre CFO effective June 1, 2026.
-
Appointment Of Cost Auditor Of The Company For The Financial Year 2026-27
15h - Board approved FY26 audited results, recommended Rs1 dividend, appointed new CFO effective June 1, 2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
15h - Board approved FY26 audited results, recommended Re.1 dividend, and appointed Pranav Chitre CFO from June 1, 2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
15h - Board approved FY26 audited results, Re1 dividend, CFO appointment, and executive re-designation on May 26, 2026.
-
Appointment Of Internal Auditor Of The Company For FY 2026-27
15h - FY26 audited results approved; Re.1 dividend recommended; Pranav Chitre appointed CFO from June 1, 2026.
Concalls
-
Apr 2026Transcript PPT REC
Business Profile[1]
The Company is a research-driven agrochemical company with 40+ years of experience since 1985, focused on the development, manufacturing, and distribution of crop protection products across two verticals — Formulations (finished products) and Technicals (active ingredients).